XENE

Xenon Pharmaceuticals Inc

38.23

Nov 03 • 3:59 PM ET +0.61 (1.62%)

38.10

Aftermarket • 7:30 PM ET -0.13 (-0.34%)

Healthcare Biotechnology Canada Mid NASD

Peers: BHVN PRAX RAPP JAZZ DRUG STOK OVID AXSM SUPN NBIX

| Held by: IWM IWO IBB VTWO TCAF SPDW FESM SBIO VTWG TMSL

Scroll to Statements

Index	RUT
Market Cap	3.70B
Enterprise Value	2.78B
Income	-409.20M
Sales	0.00M
Book/sh	12.84
Cash/sh	9.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	370
IPO	Nov 05, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.98
P/C	3.98
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	21.02
Current Ratio	21.02
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.74
EPS next Y	-4.67
EPS next Q	-1.13
EPS this Y	-5.56%
EPS next Y	-1.40%
EPS next 5Y	8.95%
EPS past 3/5Y	-28.36% -40.02%
Sales past 3/5Y	-7.36% -25.26%
EPS Y/Y TTM	-33.88%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-3.62%
Sales Q/Q	-
Earnings	Nov 09 AMC
EPS/Sales Surpr.	2.76% -100.00%

Insider Own	5.26%
Insider Trans	0.50%
Inst Own	100.45%
Inst Trans	2.36%
ROA	-41.54%
ROE	-43.62%
ROIC	-32.80%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.34%
SMA50	-13.97%
SMA200	-26.96%
Trades

Shs Outstand	96.75M
Shs Float	91.74M
Short Float	8.01%
Short Ratio	4.82
Short Interest	7.35M
52W High	72.66 -47.39%
52W Low	33.38 14.53%
Volatility	3.42% 3.40%
ATR (14)	1.46
RSI (14)	48.43
Beta	0.08
Rel Volume	0.82
Avg Volume	1.52M
Volume	1,246,711

Perf Week	6.16%
Perf Month	1.76%
Perf Quarter	-40.54%
Perf Half Y	-33.75%
Perf YTD	-14.70%
Perf Year	-7.03%
Perf 3Y	16.27%
Perf 5Y	12.11%
Perf 10Y	396.49%
Recom	1.17
Target Price	71.75
Prev Close	37.62
Price	38.23
Change %	1.62%

Consensus

Strong Buy

Avg. Price Target

$71.75

Implied Upside

+87.7%

Analysts16incl. previous ratings

Rating Distribution15 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 06, 2026	Resumed	GGuggenheim	Buy	$73	+90.9%
Sep 18, 2026	Downgrade	DDeutsche Bank	Buy → Hold	$46	+20.3%
Feb 24, 2026	Initiated	WWolfe Research	Outperform	$60	+56.9%
Sep 03, 2025	Resumed	WWells Fargo	Overweight	$48	+25.6%
May 07, 2025	Initiated	CChardan Capital Markets	Buy	$55	+43.9%
Feb 11, 2025	Initiated	DDeutsche Bank	Buy	$67	+75.3%
Oct 10, 2024	Resumed	RRaymond James	Outperform	$50	+30.8%
Oct 01, 2024	Initiated	HH.C. Wainwright	Buy	$53	+38.6%
Jan 04, 2024	Initiated	CCitigroup	Buy	$62	+62.2%
Dec 08, 2023	Initiated	RRobert W. Baird	Outperform	$63	+64.8%
Oct 24, 2023	Resumed	CCantor Fitzgerald	Overweight
Apr 25, 2023	Initiated	CCantor Fitzgerald	Overweight	$58	+51.7%
Dec 14, 2022	Initiated	GGoldman	Buy	$60	+56.9%
Dec 12, 2022	Initiated	CCowen	Outperform
Nov 28, 2022	Initiated	WWells Fargo	Overweight	$50	+30.8%
Oct 19, 2022	Initiated	RRaymond James	Outperform	$52	+36.0%
Aug 29, 2022	Initiated	BBofA Securities	Buy	$45	+17.7%
Jul 21, 2022	Initiated	JJP Morgan	Overweight	$55	+43.9%
Oct 28, 2021	Initiated	RRBC Capital Mkts	Outperform	$43	+12.5%
Oct 02, 2020	Initiated	SSVB Leerink	Outperform	$22	-42.5%

Nov-03-26 04:01PM	Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
02:13PM	Xenon's NDA Filing Status Takes Center Stage After A 40% Slide Despite Upbeat Guidance (Earnings Whispers)
Nov-02-26 04:01PM	Xenon to Report Q3 2026 Financial Results on November 9, 2026 (GlobeNewswire)
Oct-30-26 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-26 08:30AM	Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain (GlobeNewswire)
09:14AM	Loading…
Oct-20-26 09:14AM	Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging (Barrons.com)
Oct-02-26 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-26 12:10PM	Xenons Insider Buying Tops $1.6M XENE Stock Heads For Best Day In Over Month (Stocktwits)
Sep-29-26 08:00AM	Ian Mortimer Receives the 2026 Bloom Burton Award (TMX Newsfile)
03:15AM	Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors (TMX Newsfile)
Sep-21-26 04:01PM	Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (GlobeNewswire)
07:37AM	Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment (TIKR)
Sep-18-26 04:09PM	This Biotech Surged 50% On Positive Data In March. Now, It's Completely Gone. (Investor's Business Daily) -30.69%
11:27AM	Xenon Pharmaceuticals falls 30% after depression trial enrollment pause (Proactive)
09:36AM	Netflix downgraded, Etsy upgraded: Wall Street's top analyst calls (The Fly)
08:08AM	Loading…
08:08AM	Premarket movers: Xenon sinks on trial pause, Netflix hit by downgrade (Investing.com)
07:32AM	Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword (Barrons.com)
04:48AM	Premarket movers: Intel, Coinbase, Nucor and Xenon (MarketWatch)
03:37AM	Stock Market Today: Dow set to slip, S&P 500 and Nasdaq head for steady open as oil prices dip but yields tick higher (MarketWatch)
Sep-17-26 04:01PM	Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program (GlobeNewswire)
Sep-10-26 02:14PM	Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. (Barrons.com)
Sep-03-26 04:01PM	Xenon to Present at Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-28-26 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-26 04:01PM	Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 (GlobeNewswire) +5.58%
Aug-07-26 01:09AM	Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ... (GuruFocus.com)
Aug-06-26 04:32PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
04:01PM	Xenon Reports Q2 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-26 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-26 04:01PM	Xenon to Report Q2 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-02-26 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:01PM	Loading…
May-29-26 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 04:34PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
04:01PM	Xenon Reports Q1 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-01-26 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Three Finalists Announced for the 2026 Bloom Burton Award (TMX Newsfile)
Apr-30-26 04:01PM	Xenon to Report Q1 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-19-26 06:00PM	Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting (GlobeNewswire)
Apr-15-26 08:30AM	Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-07-26 08:30AM	Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting (GlobeNewswire)
Mar-12-26 04:01PM	Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Mar-11-26 06:00AM	Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00 (TipRanks)
Mar-10-26 10:39PM	Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering (GlobeNewswire)
11:26AM	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study (Zacks)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 07:00PM	50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today (24/7 Wall St.) +49.64%
04:25PM	Xenon Smashes Its Previous Record High On 'Unprecedented' Results. Is A Buyout Next? (Investor's Business Daily)
04:01PM	Xenon Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
01:50PM	Analysts tout market potential of Xenons epilepsy drug on Phase III win (Clinical Trials Arena)
11:47AM	What's Going On With Biohaven Stock On Monday? (Benzinga)
09:26AM	Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures (Benzinga)
07:00AM	Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) (GlobeNewswire)
Mar-08-26 02:00PM	Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 (GlobeNewswire)
Mar-04-26 01:36PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
Feb-27-26 09:37AM	Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Feb-26-26 05:04PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 01:08PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Jan-20-26 10:42AM	3 Biotech Stocks That Could Double In 2026 (24/7 Wall St.)
Jan-16-26 04:05PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 08:30AM	Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:30AM	Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.07%
Dec-05-25 09:00AM	Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire)
Dec-04-25 05:20PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? (Zacks)
08:30AM	Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 (GlobeNewswire)
Nov-25-25 08:30AM	Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire)
Nov-06-25 08:30AM	Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-04-25 09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
12:01AM	Xenon Pharmaceuticals Inc (XENE) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Nov-03-25 04:32PM	Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Third Quarter 2025 Financial Results & Business Update (GlobeNewswire)
Oct-27-25 08:30AM	Xenon to Report Q3 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-16-25 08:30AM	Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer (GlobeNewswire)
Oct-07-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-25 04:01PM	Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? (Zacks)
Aug-29-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +5.51%
03:06AM	Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Aug-11-25 06:03PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Second Quarter 2025 Financial Results & Business Update (GlobeNewswire)
Aug-04-25 08:01AM	Xenon to Report Q2 2025 Financial Results on August 11, 2025 (GlobeNewswire) +8.72%
Aug-01-25 04:55PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-25 06:30AM	Compass Pathways Appoints Justin Gover to Board of Directors (Business Wire)
Jul-02-25 03:20AM	RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug (Insider Monkey)
Jun-27-25 04:01PM	Xenon Joins the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-26-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-25 08:30AM	Xenon Announces Appointment of Darren Cline as Chief Commercial Officer (GlobeNewswire)
Jun-11-25 11:30AM	Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-03-25 04:01PM	Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-25 04:01PM	Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
08:18AM	Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday (Insider Monkey)
May-13-25 12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks) -17.43%
03:09AM	Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
May-12-25 04:10PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:24AM	Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Thomas Patrick	Chief Financial Officer	Sep 30 '26	Buy	37.32	15,000	559,740	15,000	Oct 01 09:20 AM
MORTIMER IAN	PRESIDENT & CEO	Sep 30 '26	Buy	37.38	30,000	1,121,400	49,923	Oct 01 09:19 AM
Svoronos Dawn	Director	Sep 01 '26	Option Exercise	8.15	5,144	41,924	31,373	Sep 03 08:26 PM
KENNEY CHRISTOPHER JOHN	Chief Medical Officer	Aug 28 '26	Sale	60.25	7,068	425,829	2	Aug 31 09:59 PM
CHRISTOPHER KENNEY	Officer	Aug 28 '26	Proposed Sale	61.93	7,068	437,721		Aug 28 04:25 PM
GANNON STEVEN	Director	Aug 11 '26	Sale	64.06	10,000	640,550	1,870	Aug 13 04:33 PM
STEVEN GANNON	Director	Aug 11 '26	Proposed Sale	64.06	10,000	640,553		Aug 13 04:30 PM
PATOU GARY	Director	Jun 05 '26	Sale	53.14	1,322	70,251	24,896	Jun 08 09:19 PM
Cannon Gillian	Director	Jun 05 '26	Sale	53.14	1,190	63,237	1,455	Jun 08 09:19 PM
GILLIAN CANNON	Director	Jun 05 '26	Proposed Sale	52.99	1,190	63,058		Jun 05 04:32 PM
GARY PATOU	Director	Jun 05 '26	Proposed Sale	52.99	1,322	70,053		Jun 05 04:32 PM
GANNON STEVEN	Director	May 12 '26	Option Exercise	7.38	3,500	25,830	10,641	May 13 09:40 PM
KENNEY CHRISTOPHER JOHN	Chief Medical Officer	Mar 13 '26	Sale	55.23	1,410	77,867	7,069	Mar 13 08:16 PM
DiFabio Andrea	Chief Legal Officer	Mar 13 '26	Sale	55.23	1,342	74,112	7,301	Mar 13 08:16 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 13 '26	Sale	55.23	7,308	403,584	19,923	Mar 13 08:16 PM
CHRISTOPHER JOHN KENNEY	Officer	Mar 13 '26	Proposed Sale	55.22	1,410	77,867		Mar 13 07:51 PM
ANDREA DIFABIO	Officer	Mar 13 '26	Proposed Sale	55.23	1,342	74,112		Mar 13 07:50 PM
IAN MORTIMER	Officer	Mar 13 '26	Proposed Sale	55.22	7,308	403,583		Mar 13 07:49 PM
KENNEY CHRISTOPHER JOHN	Chief Medical Officer	Mar 10 '26	Sale	60.11	2,771	166,559	4,729	Mar 11 07:21 PM
DiFabio Andrea	Chief Legal Officer	Mar 10 '26	Sale	60.11	2,607	156,702	4,893	Mar 11 07:20 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 09 '26	Option Exercise	6.74	270,000	1,819,850	111,000	Mar 11 07:20 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 09 '26	Sale	60.33	270,000	16,289,142	6,000	Mar 11 07:20 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 10 '26	Sale	60.11	11,269	677,357	14,731	Mar 11 07:20 PM
ANDREA DIFABIO	Officer	Mar 10 '26	Proposed Sale	60.11	2,607	156,702		Mar 10 09:01 PM
CHRISTOPHER JOHN KENNEY	Officer	Mar 10 '26	Proposed Sale	60.11	2,771	166,559		Mar 10 08:58 PM
IAN MORTIMER	Officer	Mar 10 '26	Proposed Sale	60.11	11,269	677,357		Mar 10 08:57 PM
IAN MORTIMER	Officer	Mar 09 '26	Proposed Sale	60.33	270,000	16,289,196		Mar 09 04:46 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 02 '26	Option Exercise	7.49	40,000	299,600	46,000	Jan 02 06:49 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 02 '26	Sale	44.43	40,000	1,777,093	6,000	Jan 02 06:49 PM
IAN MORTIMER	Officer	Jan 02 '26	Proposed Sale	44.43	40,000	1,777,166		Jan 02 06:47 PM
MORTIMER IAN	PRESIDENT & CEO	Dec 05 '25	Sale	45.03	14,375	647,306	16,830	Dec 09 07:40 PM
MORTIMER IAN	PRESIDENT & CEO	Dec 08 '25	Sale	45.73	10,830	495,207	6,000	Dec 09 07:40 PM
IAN MORTIMER	Officer	Dec 08 '25	Proposed Sale	45.73	10,830	495,248		Dec 08 05:10 PM
IAN MORTIMER	Officer	Dec 05 '25	Proposed Sale	45.03	14,375	647,360		Dec 05 05:54 PM
MORTIMER IAN	PRESIDENT & CEO	Nov 28 '25	Sale	45.01	97	4,366	31,205	Dec 03 08:20 PM
IAN MORTIMER	Officer	Nov 28 '25	Proposed Sale	45.01	97	4,366		Dec 01 07:36 PM

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

CPAMr. Ian C. Mortimer C.M.A.

Chief Financial OfficerMr. Thomas Patrick Kelly J.D.

Chief Legal Officer & Corporate SecretaryMs. Andrea DiFabio J.D.

Chief Medical OfficerDr. Christopher John Kenney M.D.

Chief Commercial OfficerMr. Darren S. Cline M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XENE

Xenon Pharmaceuticals Inc

Upgrade your Finviz experience